CN113229498A - 一种有助于降低血压药食同源组合物组方及其制备工艺 - Google Patents
一种有助于降低血压药食同源组合物组方及其制备工艺 Download PDFInfo
- Publication number
- CN113229498A CN113229498A CN202110559269.3A CN202110559269A CN113229498A CN 113229498 A CN113229498 A CN 113229498A CN 202110559269 A CN202110559269 A CN 202110559269A CN 113229498 A CN113229498 A CN 113229498A
- Authority
- CN
- China
- Prior art keywords
- parts
- blood pressure
- medicinal
- weight
- raw materials
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 57
- 230000036772 blood pressure Effects 0.000 title claims abstract description 51
- 238000002360 preparation method Methods 0.000 title claims abstract description 19
- 230000009467 reduction Effects 0.000 title description 3
- 238000011946 reduction process Methods 0.000 title description 2
- 239000002994 raw material Substances 0.000 claims abstract description 35
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 27
- 230000001603 reducing effect Effects 0.000 claims abstract description 24
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 19
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 19
- 240000008042 Zea mays Species 0.000 claims abstract description 19
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims abstract description 18
- 240000000950 Hippophae rhamnoides Species 0.000 claims abstract description 18
- 235000003145 Hippophae rhamnoides Nutrition 0.000 claims abstract description 18
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 18
- 235000003130 Arctium lappa Nutrition 0.000 claims abstract description 17
- 235000008078 Arctium minus Nutrition 0.000 claims abstract description 17
- 235000007516 Chrysanthemum Nutrition 0.000 claims abstract description 17
- 235000009917 Crataegus X brevipes Nutrition 0.000 claims abstract description 16
- 235000013204 Crataegus X haemacarpa Nutrition 0.000 claims abstract description 16
- 235000009685 Crataegus X maligna Nutrition 0.000 claims abstract description 16
- 235000009444 Crataegus X rubrocarnea Nutrition 0.000 claims abstract description 16
- 235000009486 Crataegus bullatus Nutrition 0.000 claims abstract description 16
- 235000017181 Crataegus chrysocarpa Nutrition 0.000 claims abstract description 16
- 235000009682 Crataegus limnophila Nutrition 0.000 claims abstract description 16
- 235000004423 Crataegus monogyna Nutrition 0.000 claims abstract description 16
- 235000002313 Crataegus paludosa Nutrition 0.000 claims abstract description 16
- 235000009840 Crataegus x incaedua Nutrition 0.000 claims abstract description 16
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 16
- 244000197580 Poria cocos Species 0.000 claims abstract description 16
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 16
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 16
- 235000005822 corn Nutrition 0.000 claims abstract description 16
- 244000131316 Panax pseudoginseng Species 0.000 claims abstract description 14
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims abstract description 14
- 238000000034 method Methods 0.000 claims abstract description 11
- 210000000582 semen Anatomy 0.000 claims abstract description 7
- 240000005528 Arctium lappa Species 0.000 claims abstract 4
- 240000000171 Crataegus monogyna Species 0.000 claims abstract 4
- 239000007788 liquid Substances 0.000 claims description 28
- 238000000605 extraction Methods 0.000 claims description 21
- 239000000843 powder Substances 0.000 claims description 19
- 238000002156 mixing Methods 0.000 claims description 15
- 240000000249 Morus alba Species 0.000 claims description 14
- 235000008708 Morus alba Nutrition 0.000 claims description 14
- 244000037364 Cinnamomum aromaticum Species 0.000 claims description 12
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 claims description 12
- 244000046146 Pueraria lobata Species 0.000 claims description 12
- 235000010575 Pueraria lobata Nutrition 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 11
- 238000001694 spray drying Methods 0.000 claims description 11
- 238000010992 reflux Methods 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 7
- 235000005911 diet Nutrition 0.000 claims description 6
- 230000000378 dietary effect Effects 0.000 claims description 6
- 239000002245 particle Substances 0.000 claims description 4
- 238000000926 separation method Methods 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 3
- 235000003599 food sweetener Nutrition 0.000 claims description 2
- 239000003765 sweetening agent Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims 7
- 230000000694 effects Effects 0.000 abstract description 45
- 239000003814 drug Substances 0.000 abstract description 37
- 229940079593 drug Drugs 0.000 abstract description 15
- 229940126673 western medicines Drugs 0.000 abstract description 7
- 230000009286 beneficial effect Effects 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 6
- 230000035622 drinking Effects 0.000 abstract description 5
- 231100000331 toxic Toxicity 0.000 abstract description 5
- 230000002588 toxic effect Effects 0.000 abstract description 5
- 206010031127 Orthostatic hypotension Diseases 0.000 abstract description 4
- 238000011031 large-scale manufacturing process Methods 0.000 abstract description 4
- 231100000957 no side effect Toxicity 0.000 abstract description 4
- 241000721047 Danaus plexippus Species 0.000 abstract description 3
- 208000001089 Multiple system atrophy Diseases 0.000 abstract description 3
- 244000269722 Thea sinensis Species 0.000 abstract description 3
- 239000000243 solution Substances 0.000 description 40
- 239000000284 extract Substances 0.000 description 30
- 210000004369 blood Anatomy 0.000 description 20
- 239000008280 blood Substances 0.000 description 20
- 230000001737 promoting effect Effects 0.000 description 19
- 210000004185 liver Anatomy 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 14
- 235000013305 food Nutrition 0.000 description 14
- 239000008213 purified water Substances 0.000 description 14
- 238000011160 research Methods 0.000 description 13
- 241000208843 Arctium Species 0.000 description 12
- 241001092040 Crataegus Species 0.000 description 12
- 206010020772 Hypertension Diseases 0.000 description 12
- 238000012360 testing method Methods 0.000 description 11
- 241000180649 Panax notoginseng Species 0.000 description 10
- 210000002216 heart Anatomy 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 235000003143 Panax notoginseng Nutrition 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 8
- RNXZPKOEJUFJON-UHFFFAOYSA-N aurantio-obtusin Chemical compound CC1=C(O)C(OC)=C2C(=O)C3=C(O)C(OC)=C(O)C=C3C(=O)C2=C1 RNXZPKOEJUFJON-UHFFFAOYSA-N 0.000 description 8
- 229930003944 flavone Natural products 0.000 description 8
- 150000002212 flavone derivatives Chemical class 0.000 description 8
- 235000011949 flavones Nutrition 0.000 description 8
- 210000000952 spleen Anatomy 0.000 description 8
- 210000002784 stomach Anatomy 0.000 description 8
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 8
- 238000011049 filling Methods 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- 210000004072 lung Anatomy 0.000 description 7
- 229930182490 saponin Natural products 0.000 description 7
- 150000007949 saponins Chemical class 0.000 description 7
- 235000017709 saponins Nutrition 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 235000009508 confectionery Nutrition 0.000 description 6
- 206010016256 fatigue Diseases 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- 238000007873 sieving Methods 0.000 description 6
- 208000002193 Pain Diseases 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 230000004438 eyesight Effects 0.000 description 5
- 229930003935 flavonoid Natural products 0.000 description 5
- 235000017173 flavonoids Nutrition 0.000 description 5
- 150000004676 glycans Chemical class 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 229920001282 polysaccharide Polymers 0.000 description 5
- 239000005017 polysaccharide Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 206010028980 Neoplasm Diseases 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229930013930 alkaloid Natural products 0.000 description 4
- MWPLVEDNUUSJAV-UHFFFAOYSA-N anthracene Chemical compound C1=CC=CC2=CC3=CC=CC=C3C=C21 MWPLVEDNUUSJAV-UHFFFAOYSA-N 0.000 description 4
- 230000001914 calming effect Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 150000002215 flavonoids Chemical class 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 150000003648 triterpenes Chemical class 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 208000006083 Hypokinesia Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 206010036790 Productive cough Diseases 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 235000007244 Zea mays Nutrition 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 150000003797 alkaloid derivatives Chemical class 0.000 description 3
- 235000019658 bitter taste Nutrition 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 208000026106 cerebrovascular disease Diseases 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 208000002173 dizziness Diseases 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- 208000007530 Essential hypertension Diseases 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 241000229143 Hippophae Species 0.000 description 2
- 235000003935 Hippophae Nutrition 0.000 description 2
- 206010062717 Increased upper airway secretion Diseases 0.000 description 2
- 206010033557 Palpitations Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 229940089639 cornsilk Drugs 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 2
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 239000011259 mixed solution Substances 0.000 description 2
- YTJSFYQNRXLOIC-UHFFFAOYSA-N octadecylsilane Chemical compound CCCCCCCCCCCCCCCCCC[SiH3] YTJSFYQNRXLOIC-UHFFFAOYSA-N 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 208000026435 phlegm Diseases 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 2
- 239000012088 reference solution Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 230000035807 sensation Effects 0.000 description 2
- 235000019615 sensations Nutrition 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 235000019640 taste Nutrition 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 230000035922 thirst Effects 0.000 description 2
- 235000013619 trace mineral Nutrition 0.000 description 2
- 239000011573 trace mineral Substances 0.000 description 2
- 230000002936 tranquilizing effect Effects 0.000 description 2
- 239000001231 zea mays silk Substances 0.000 description 2
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical class C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- XOJVHLIYNSOZOO-SWOBOCGESA-N Arctiin Chemical compound C1=C(OC)C(OC)=CC=C1C[C@@H]1[C@@H](CC=2C=C(OC)C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)=CC=2)C(=O)OC1 XOJVHLIYNSOZOO-SWOBOCGESA-N 0.000 description 1
- 244000294263 Arctium minus Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 239000004072 C09CA03 - Valsartan Substances 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 229940127291 Calcium channel antagonist Drugs 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 244000277285 Cassia obtusifolia Species 0.000 description 1
- 235000006719 Cassia obtusifolia Nutrition 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- 241000146989 Engraulis japonicus Species 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 229930189092 Notoginsenoside Natural products 0.000 description 1
- 241000209477 Nymphaeaceae Species 0.000 description 1
- CFLNHFUPWNRWJA-UHFFFAOYSA-N Obtusin Chemical compound O=C1C2=CC(C)=C(O)C(OC)=C2C(=O)C2=C1C=C(OC)C(OC)=C2O CFLNHFUPWNRWJA-UHFFFAOYSA-N 0.000 description 1
- OBBJQZSMXOJMCN-UHFFFAOYSA-N Obtusin Natural products COc1cc2C=CC(=O)Oc2c3OCC(Oc13)C(=C)C OBBJQZSMXOJMCN-UHFFFAOYSA-N 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000209504 Poaceae Species 0.000 description 1
- 241000222341 Polyporaceae Species 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010057071 Rectal tenesmus Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 241001558929 Sclerotium <basidiomycota> Species 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010057469 Vascular stenosis Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 208000021017 Weight Gain Diseases 0.000 description 1
- 208000005946 Xerostomia Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 235000019606 astringent taste Nutrition 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- -1 flavonoid compound Chemical class 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- PWAOOJDMFUQOKB-WCZZMFLVSA-N ginsenoside Re Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]3C(C)(C)[C@@H](O)CC[C@]3(C)[C@@H]3[C@@]([C@@]4(CC[C@@H]([C@H]4[C@H](O)C3)[C@](C)(CCC=C(C)C)O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)C)(C)C2)O[C@H](CO)[C@@H](O)[C@@H]1O PWAOOJDMFUQOKB-WCZZMFLVSA-N 0.000 description 1
- AOGZLQUEBLOQCI-UHFFFAOYSA-N ginsenoside-Re Natural products CC1OC(OCC2OC(OC3CC4(C)C(CC(O)C5C(CCC45C)C(C)(CCC=C(C)C)OC6OC(CO)C(O)C(O)C6O)C7(C)CCC(O)C(C)(C)C37)C(O)C(O)C2O)C(O)C(O)C1O AOGZLQUEBLOQCI-UHFFFAOYSA-N 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000003779 hair growth Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 206010020765 hypersomnia Diseases 0.000 description 1
- 208000021822 hypotensive Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000004377 improving vision Effects 0.000 description 1
- 230000000622 irritating effect Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 229960001597 nifedipine Drugs 0.000 description 1
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 208000030212 nutrition disease Diseases 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 239000008678 sanqi Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 208000012271 tenesmus Diseases 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 description 1
- 229960004699 valsartan Drugs 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/734—Crataegus (hawthorn)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种有助于降低血压药食同源组合物组方,包括以下重量份的原料:三七花5‑15重量份、玉米须10‑20重量份、茯苓10‑20重量份、桑叶6‑15重量份、荷叶2‑8重量份、牛蒡根5‑15重量份、山楂5‑15重量份、葛根10‑20重量份、沙棘2‑8重量份、决明子5‑15重量份、菊花1‑5重量份;按照中医君臣佐使用药配伍关系,诸药合用,共奏降压功效,相比西药无***性低血压危险,其他中药产品效果单一,疗效较差。此方组合,无副作用,疗效确切;本产品为纯中药制剂,且全部为药食同源原料,安全有效。相比西药,无毒副作用。同时提供了一种可实现规模化生产的工艺路线,制备工艺简单可靠,有效成分提取较完全,可直接冲服饮用。
Description
技术领域
本发明属于食品领域的药食同源组合物技术,尤其涉及一种有助于降低血压药食同源组合物组方及其制备工艺。
背景技术
随着现代科学的迅速发展,我国人民生活水平的提高,膳食结构的改变,工作节奏的加快,高血压发病率逐步上升,目前我国正以每年新增300万人的速度发展,高血压病是一种常见的心脑血管疾病,它可引起动脉粥样硬化,使动脉管腔狭窄而阻碍血液流通,是冠心病和脑血管病的主要危险因素,也是造成肢体偏瘫、心力衰竭、脑梗塞、脑出血、肾衰竭的重要原因,临床上因高血压病发生致残致死的病例屡见不鲜,全国每年导致120万人死亡,故学者称之谓“隐形杀手”。根据最新发布的《中国居民营养与慢性病状况报告(2020年)》数据显示,我国18岁及以上居民高血压患病率为27.5%,糖尿病患病率为11.9%,高胆固醇血症患病率为8.2%,高血压暂居前列,总人数约高达3亿人,高血压防治现况不容乐观,其已成为我国人群因病致死、致残的首因。
目前临床上治疗高血压的化学药物主要有血管紧张素II受体拮抗剂(ARB类药物)、血管紧张素转化酶抑制剂(ACEI类药物)、β受体阻滞剂、钙离子拮抗剂(CCB类药物)、利尿药。但长期服用易产生血钾增高、咳嗽、***性低血压等副作用。与之相比,中医药降低血压遵循中医药辨证理论,通过调整脏腑气血阴阳,使机体恢复正常状态。
发明内容
针对现有技术中的缺陷,本发明提供一种有助于降低血压药食同源组合物组方及其制备工艺,按照中医君臣佐使用药配伍关系,诸药合用,共奏降压功效,相比西药无***性低血压危险,其他中药产品效果单一,疗效较差。此方组合,无副作用,疗效确切;本产品为纯中药制剂,且全部为药食同源原料,安全有效。相比西药,无毒副作用。同时提供了一种可实现规模化生产的工艺路线,制备工艺简单可靠,有效成分提取较完全,可直接冲服饮用。
本发明的一种有助于降低血压药食同源组合物组方,包括以下重量份的原料:三七花5-15重量份、玉米须10-20重量份、茯苓10-20重量份、桑叶6-15重量份、荷叶2-8重量份、牛蒡根5-15重量份、山楂5-15重量份、葛根10-20重量份、沙棘2-8重量份、决明子5-15重量份、菊花1-5重量份。
药食两用原料之玉米须:本品为禾本科植物玉米Zea mays L.的干燥花丝和柱头,味甘,性平和。归肝、胆、胃、肾经。玉米须主要成分是黄酮及其苷、糖、甾醇、有机酸、生物碱、挥发油等。其中,黄酮及其苷为主要发挥作用的成分。玉米须具有利尿消肿、降血压的功效。其水浸液和乙醇浸出液对犬、猫及家兔有显著降压作用,在低浓度时对末梢血管有扩张作用。现代研究表明,玉米须还具有利尿、抑菌、抗凝血、降血糖、增强免疫等作用。
药食两用原料之三七花:味甘微苦,归肝、肾经,具有清热生津、平肝降压的作用。其主要活性成分为三七花总皂苷,它也是三七全株中三七皂苷含量最高的部分。采用三七花总皂苷灌胃原发性高血压大鼠(SHR)实验,发现三七花大、中、小剂量降压存在明显量效关系,且对SHR大鼠心率无显著影响,可见三七花总皂苷能取得较好的降压作用,其具体机制可能是直接扩张血管,其次可能是抑制血管运动中枢所致。
药食两用原料之茯苓:本品为多孔菌科真菌茯苓Poria cocos(Schw.)Wolf的干燥菌核。味甘、淡,性平。归心、肺、脾、肾经。茯苓的主要成分为多糖、三萜、脂肪酸、甾醇、酶等。其中,多糖和三萜是主要发挥作用的成分。茯苓具有利水渗湿、健脾胃、宁心神的功效。可使平滑肌收缩振幅减少,张力下降。现代研究表明,茯苓有保护肝脏、抗癌、抗炎、抗病毒、抗菌、利水、镇静、抗衰老、抗惊厥等作用。
药食两用原料之山楂:本品为蔷薇科植物山里红Cralaeguspinnatifida.Bge.var.major N.E.Br的干燥成熟果实。味酸、甘,性微温。归胃、脾、肝经。山楂的主要成分是黄酮类、鞣质、糖类、有机酸类、微量元素。黄酮类化合物是主要活性成分。山楂有消食健胃、行气散瘀、化浊降脂的功效。现代药理研究表明,山楂还有降血脂、降血压、抗氧化、抗菌、抗肿瘤等作用。
药食两用原料之牛蒡根:味苦,药性寒;归肺经。具有疏散风热宣肺透疹、解毒利咽的功效。现代药理学研究发现,牛蒡根具有促进生长发育、抗真菌等作用。
药食两用原料之决明子:本品为豆科植物决明Cassia obtusifolia L.的干燥成熟种子。性微寒,味苦、甘、微咸。归大肠、肝经。决明子的化学成分包括蒽醍类、糖、氨基酸、微量元素等。其中,蒽醍类是主要发挥作用的成分。决明子具有清热明目、润肠通便的功效。现代研究表明,决明子有降血压、降血脂、保护肝脏、调节免疫、缓泻、抗菌等作用。
药食两用原料之桑叶:本品为桑科植物桑Morus alba L.的干燥叶。味甘、苦,性寒。归肺、肝经。桑叶的主要成分为黄酮类、多糖、酚类、生物碱、挥发油等。其中,黄酮类化合物是主要活性成分。桑叶有疏散风热、清肺润燥、清肝明目的功效。现代研究表明,桑叶还有抗凝血、抗炎、抗氧化、抗病毒、抗疲劳、降血糖、降血脂等作用。
药食两用原料之葛根:本品为豆科植物野葛Pueraria lobata(Willd.)Ohwi的干燥根。性凉,味辛、甘。归肺、脾、胃经。葛根的化学成分包括黄酮、香豆素、生物碱、皂苷、三萜等。其中黄酮是主要发挥作用的成分。葛根具有生津止渴、解肌退热、升阳止泻、通经活络、透疹、解酒毒的功效。现代研究表明,葛根具有降血压、抗心律失常、抗肿瘤、抗氧化、提高免疫力、止泻、改善骨代谢等作用。
药食两用原料之荷叶:本品为睡莲科植物莲Nelumbo nucifera Gaertn.的干燥叶。味苦,性平。归肝、脾、胃经。荷叶的主要成分有生物碱、黄酮、多酚、三菇、多糖等,其中生物碱和黄酮是主要发挥作用的成分。荷叶具有清暑化湿、升发清阳、凉血止血的功效。现代研究显示,荷叶还具有镇静、催眠、抗氧化、抑菌、抗病毒、降血脂、止血的功效。
药食两用原料之沙棘:为胡颓子科植物沙棘Hippophae rhamnoides L.的干燥成熟果实。味酸、涩,性温。归胃、脾、心、肺经。黄酮类化合物是沙棘主要活性成分。沙棘有健脾消食、止咳祛痰、活血散瘀的功效。现代研究表明,沙棘还能抗氧化、抗肝损伤、抗胃溃疡、调节血糖等作用。
药食两用原料之菊花:本品为菊科植物菊Chrysanthemum morifolium Ramat.的干燥头状花序。性偏寒,味苦、甘。归肺、肝经。菊花的化学成分包括黄酮、三萜、挥发油、甾醇、多糖、微量元素、氨基酸等。其中,黄酮是主要发挥作用的成分。菊花具有散风清热、平肝明目、清热解毒的功效。现代研究表明,菊花具有抗病原微生物、抗肿瘤、抗疲劳、抗炎、抗衰老、抗氧化、降血压、降血脂、保护心肌等作用。
本发明配方按照中医君臣佐使用药配伍关系:三七花具有清热生津、平肝降压,菊花平肝降压、清热明目,决明子清肝明目降压,共为君药;玉米须具有利尿消肿、降血压,山楂消食健胃、行气散淤、化浊降脂,沙棘止咳止痰、活血散瘀,共为臣药;葛根生津止渴、通经活络,桑叶清热平肝,茯苓利水渗湿、宁心神,为佐药;牛蒡根疏散风热,荷叶清暑化湿,为使药。诸药合用,共奏降压功效。
三七花、玉米须扩张血管而达到降压效果,山楂、沙棘行气散淤、化浊降脂,改变血管通透性而降低血压,诸药合用平稳缓慢降低血压。相比西药无***性低血压危险,其他中药产品效果单一,疗效较差。此方组合,无副作用,疗效确切。
本产品为纯中药制剂,且全部为药食同源原料,安全有效。相比西药,无毒副作用。
进一步,各原料重量份具体如下:三七花12重量份、玉米须15重量份、茯苓15重量份、桑叶10重量份、荷叶6重量份、牛蒡根12重量份、山楂12重量份、葛根15重量份、沙棘6重量份、决明子10重量份、菊花3重量份。该重量份药食同源组合物符合临床中医用药的配伍关系,实验表明,该配伍关系下,所制得的组合物的符合食品安全要求,有效成分含量最高、有效成分转移率较高以及整体出膏率最高。
本发明的一种有助于降低血压药食同源组合物组方的制备工艺,具体包括以下步骤:
步骤1:按重量份称取三七花、玉米须、茯苓、桑叶、荷叶、牛蒡根、山楂、葛根、沙棘、决明子、菊花混合为混合料;
步骤2:将步骤1中的混合料进行粉碎,获得混合料颗粒;
步骤3:将步骤2中的混合料颗粒采用连续回流提取,获得提取液;
步骤4:将步骤3中所得提取液进行固液分离,获得澄清液,澄清液的颜色为棕褐色或黑棕色,清澈明亮,室温下密度为1.005~1.010g/cm3,PH值为7.20~7.30;
步骤5:将步骤4所得澄清液进行浓缩,获得浓缩液;浓缩液的颜色为黑棕色,较黏稠,稍粘壁,室温下密度为1.05~1.15g/cm3(60℃),PH值为7.60~7.80;
步骤6:将步骤5所得浓缩液进行喷雾干燥,获得干膏粉,干膏粉颜色为褐色,水分为3%-4%;
步骤7:将步骤6所得干膏粉中添加辅料获得药食同源组合物,所述辅料包含甜味剂0.1~0.5g/100g。
采用此种提取工艺,相较于一般常规工艺(煎煮提取、浓缩、干燥、粉碎),本发明的工艺可以达到有效成分含量提取率较高、有效成分转移率较高以及整体出膏率最高的优点。提供了一种可实现规模化生产的工艺路线,制备工艺简单可靠,有效成分提取较完全,可直接冲服饮用。
进一步,所述步骤1中的原料的产地为道地产区。
进一步,所述步骤2中进行两次连续回流提取,第一次加水量为8~15倍原料重量,第二次加水量为6~12倍原料重量,每次提取1~2h。
进一步,所述步骤4中所述浓缩条件为:温度50~70℃,真空-0.08~-0.1Mpa,浓缩液密度为1.05~1.15g/cm3(60℃)。
进一步,所述步骤5中喷雾干燥条件为:进风温度170~200℃,出风温度80~90℃,加料速度350ml/h。
本发明的有益效果是:本发明的一种有助于降低血压药食同源组合物组方及其制备工艺,按照中医君臣佐使用药配伍关系,诸药合用,共奏降压功效,相比西药无***性低血压危险,其他中药产品效果单一,疗效较差。此方组合,无副作用,疗效确切;本产品为纯中药制剂,且全部为药食同源原料,安全有效。相比西药,无毒副作用。同时提供了一种可实现规模化生产的工艺路线,制备工艺简单可靠,有效成分提取较完全,可直接冲服饮用。
具体实施方式
下面将对本发明技术方案的实施例进行详细的描述。以下实施例仅用于更加清楚地说明本发明的技术方案,因此只作为示例,而不能以此来限制本发明的保护范围。
需要注意的是,除非另有说明,本申请使用的技术术语或者科学术语应当为本发明所属领域技术人员所理解的通常意义。
实施例1:
选取三七花5重量份、玉米须10重量份、茯苓10重量份、桑叶6重量份、荷叶2重量份、牛蒡根5重量份、山楂5重量份、葛根10重量份、沙棘2重量份、决明子5重量份、菊花1重量份,混合,粉碎过10目筛;
将上述原料投入连续回流提取罐中,注入12倍量的纯化水,煎煮1.5h,获得提取液1;
再次注入10倍量的纯化水,煎煮1h,获得提取液2;
将提取液1和提取液2混合,用板框压滤机进行过滤,获得澄清液;
将澄清液注入浓缩器中进行低温浓缩,获得浓缩液;
将浓缩液喷雾干燥,得到浸膏粉;
所得浸膏粉进行灌装,即得药食同源组合物。
实施例2:
选取三七花15重量份、玉米须20重量份、茯苓20重量份、桑叶15重量份、荷叶8重量份、牛蒡根15重量份、山楂15重量份、葛根20重量份、沙棘8重量份、决明子15重量份、菊花5重量份,混合,粉碎过10目筛;
将上述原料投入连续回流提取罐中,注入12倍量的纯化水,煎煮1.5h,获得提取液1;
再次注入10倍量的纯化水,煎煮1.0h,获得提取液2;
将提取液1和提取液2混合,用板框压滤机进行过滤,获得澄清液;
将澄清液注入浓缩器中进行低温浓缩,获得浓缩液;
将浓缩液喷雾干燥,得到浸膏粉;
所得浸膏粉进行灌装,即得药食同源组合物。
实施例3:
三七花12重量份、玉米须15重量份、茯苓15重量份、桑叶10重量份、荷叶6重量份、牛蒡根12重量份、山楂12重量份、葛根15重量份、沙棘6重量份、决明子10重量份、菊花3重量份,混合,粉碎过10目筛;
将上述原料投入连续回流提取罐中,注入8倍量的纯化水,煎煮1.5h,获得提取液1;
再次注入6倍量的纯化水,煎煮1.0h,获得提取液2;
将提取液1和提取液2混合,用板框压滤机进行过滤,获得澄清液;
将澄清液注入浓缩器中进行低温浓缩,获得浓缩液;
将浓缩液用喷雾干燥,得到浸膏粉;
所得浸膏粉进行灌装,即得药食同源组合物。
实施例4:
三七花12重量份、玉米须15重量份、茯苓15重量份、桑叶10重量份、荷叶6重量份、牛蒡根12重量份、山楂12重量份、葛根15重量份、沙棘6重量份、决明子10重量份、菊花3重量份,混合,粉碎过10目筛;
将上述原料投入连续回流提取罐中,注入15倍量的纯化水,煎煮1.5h,获得提取液1;
再次注入12倍量的纯化水,煎煮1.0h,获得提取液2;
将提取液1和提取液2混合,用板框压滤机进行过滤,获得澄清液;
将澄清液注入浓缩器中进行低温浓缩,获得浓缩液;
将浓缩液用喷雾干燥,得到浸膏粉;
所得浸膏粉进行灌装,即得药食同源组合物。
实施例5:
三七花12重量份、玉米须15重量份、茯苓15重量份、桑叶10重量份、荷叶6重量份、牛蒡根12重量份、山楂12重量份、葛根15重量份、沙棘6重量份、决明子10重量份、菊花3重量份,混合,粉碎过10目筛;
将上述原料投入连续回流提取罐中,注入12倍量的纯化水,煎煮2h,获得提取液1;
再次注入10倍量的纯化水,煎煮1.0h,获得提取液2;
将提取液1和提取液2混合,用板框压滤机进行过滤,获得澄清液;
将澄清液注入浓缩器中进行低温浓缩,获得浓缩液;
将浓缩液用喷雾干燥,得到浸膏粉;
所得浸膏粉进行灌装,即得药食同源组合物。
实施例6:
选取三七花10重量份、玉米须10重量份、茯苓15重量份、桑叶10重量份、荷叶8重量份、牛蒡根10重量份、山楂5重量份、葛根15重量份、沙棘2重量份、决明子10重量份、菊花5重量份,混合,粉碎过10目筛;
将上述原料投入连续回流提取罐中,注入15倍量的纯化水,煎煮2h,获得提取液1;
再次注入12倍量的纯化水,煎煮1.0h,获得提取液2;
将提取液1和提取液2混合,用板框压滤机进行过滤,获得澄清液;
将澄清液注入浓缩器中进行低温浓缩,获得浓缩液;
将浓缩液用喷雾干燥,得到浸膏粉;
所得浸膏粉进行灌装,即得药食同源组合物。
对比例:
选取三七花12重量份、玉米须15重量份、茯苓15重量份、桑叶10重量份、荷叶6重量份、牛蒡根12重量份、山楂12重量份、葛根15重量份、沙棘6重量份、决明子10重量份、菊花3重量份;
将上述原料投入提取罐中,注入12倍量的纯化水,煎煮1.5h,获得提取液1;
再次注入10倍量的纯化水,煎煮1h,获得提取液2;
将提取液1和提取液2混合,用板框过滤进行固液分离,获得澄清液;
将澄清液注入浓缩器中进行浓缩,获得浓缩液;
将浓缩液用喷雾干燥,得到浸膏粉;
所得浸膏粉进行灌装,即得药食同源组合物。
实验例1:
本药食同源组合物维持血压健康功能试验研究
选择自发高血压大鼠(SHR),10~12周龄,体重180~220g,雌雄可以兼用,各项试验所用动物按体质量分成4组,每组12只。实验设三个剂量组和一个阴性对照组,分别为400、800、1600mg·kg-1·d-1(选用实施例5制得的样品作为受试物,分别相当于成人每日每千克体质量推荐摄入量的5倍、10倍、20倍)3个样品剂量组和阴性对照组(蒸馏水),以灌胃方式给予受试药物,同时再给予受试样品高剂量的正常动物组。受试样品给予时间30天。实验前一周对受试动物进行多次血压测量,使其适应测压环境。实验开始后每周测压2次。停止给予受试样品之后,继续观察直至血压恢复至对照组水平。如实验组动物血压明显低于对照组,差异具有显著性,且对实验组动物心率和正常动物的血压及心率无影响,可判定有助于维持血压健康水平功能动物实验结果阳性。
试验结果:
1在进行试验时所挑选的全部高血压实验动物均能正常生长,无任何异常现象。之后进行称量,发现各组大鼠体重均有不同程度增加,但所得各组间体重没有显著性差异。
表1:药食同源组合物对各组大鼠体重的影响(X±s,n=12)
2各组大鼠心率比较见表2。
表2:药食同源组合物对各组大鼠心率的影响(X±s,n=12)
组别 | 给药前 | 第1周 | 第2周 | 第3周 | 第4周 |
正常对照组 | 373.5±6.8 | 371.7±6.4 | 374.8±5.9 | 376.5±8.3 | 373.8±8.3 |
模型对照组 | 387.4±7.3 | 382.4±6.5 | 391.6±9.6 | 388.6±3.7 | 385.2±9.8 |
低剂量组 | 383.2±9.8 | 381.2±4.2 | 386.2±3.2 | 383.5±8.0 | 384.6±7.0 |
中剂量组 | 385.5±7.9 | 389.3±9.3 | 386.8±9.0 | 381.9±6.4 | 385.1±8.2 |
高剂量组 | 378.6±7.3 | 381.8±7.0 | 377.1±6.0 | 378.4±3.6 | 374.8±6.5 |
3各组SHR血压比较见表3。
注:与模型对照组比较,*表示P<0.05,**表示P<0.01
研究结果表明:由表3可见,通过对实验数据进行分析可以看出正常对照组和模型对照组收缩压和舒张压无明显变化,模型组依然维持较高血压。各剂量组给药后血压均有不同程度的降低,且随着时间的延长效果越来越明显,尤其是高剂量组。由表2可见,各剂量组对实验组动物心率和正常动物的心率无影响,故可判定药食同源组合物有助于维持血压健康水平功能动物实验结果为阳性。
实验例2:
不同提取方式的出膏率及对于组合物中有效成分含量的测定
1供试品的选择:对比例以及本公开的方法制得的组合物样品
2出膏率的测定
在对比例以及实施例的实验过程中,各取澄清液100ml,置于干燥至恒重的蒸发皿中,蒸发皿于100℃的水浴锅上挥干溶剂,转移至105℃的鼓风干燥箱中继续干燥至恒重(连续两次干燥后称重的差异在0.3mg以下的重量),称取重量,记录数据,按下式计算出膏率:
式中:P——出膏率;
m1——蒸发皿的质量(g);
m2——蒸发皿和干燥品的总质量(g);
V——样品的总体积(ml);
M——被提取原料的总质量(g)。
3三七花总皂苷的含量研究
色谱条件与***适用性试验 以十八烷基硅烷键合硅胶为填充剂;以乙腈为流动相A,以水为流动相B;按下表中的规定进行梯度洗脱;流速每分钟为1.5ml;检测波长为203nm;柱温25℃。人参皂苷Rg1与人参皂苷Re的分离度应大于1.5。理论板数按人参皂苷Rg1峰计算应不低于6000。
对照提取物溶液的制备 取三七花总皂苷对照提取物适量,精密称定,加70%甲醇溶解并稀释制成每1ml含2.5mg的溶液,即得。
供试品溶液的制备 取本品25mg,精密称定,置10ml量瓶中,加70%甲醇溶解并稀释至刻度,摇匀,即得。
测定法 分别精密吸取对照提取物溶液与供试品溶液各10μl,注入液相色谱仪,测定,即得。
4橙黄决明素的含量研究
色谱条件与***适用性试验 以十八烷基硅烷键合硅胶为填充剂;以乙腈为流动相A,以0.1%磷酸溶液为流动相B,按下表中的规定进行梯度洗脱;检测波长为284nm。理论板数按橙黄决明素峰计算应不低于3000。
对照品溶液的制备 取橙黄决明素对照品适量,精密称定,加无水乙醇-乙酸乙酯(2:1)混合溶液制成每1ml含橙黄决明素20μg的混合溶液,即得。
供试品溶液的制备 取本品25mg,精密称定,置10ml量瓶中,加70%甲醇溶解并稀释至刻度,摇匀,即得。
测定法 分别精密吸取对照品溶液与供试品溶液各10μl,注入液相色谱仪,测定,即得。
5实验结果:
上述实验结果表明:相较于常规提取工艺(即对比例),本公开发明可以略提高原料的提取出膏率以及显著提高三七花总皂苷、橙黄决明素的转移率。其中实施例5的出膏率最高,则用相同重量的原料,所制得的成品量最大,更具经济效益。
试验例3:
人群试用实验
李某某,女,55岁,高血压病史5年,长期口服缬沙坦、硝苯地平等。头昏,头顶胀痛欲裂,午后面部烘热潮红自觉气血聚于面部胀满伴有痛感,偶觉面部胀满感,视力下降,视物模糊。自觉乏力、心悸,乍觉身热即汗出,减衣物又畏寒,左臂内侧掣痛,大便难解3~4日一行,有下坠感,脾气暴躁易怒,苔黄燥,舌下络脉粗大,脉诊脉弦滑,血压170/100mmHg。口服本产品10日后患者面部烘热、胀痛大为减轻,大便通畅,心情舒畅好转,口干减,血压:140/80mmHg。续服上方一个月面部不再胀痛,头顶胀痛大减,口不干,诸症基本缓解,为巩固疗效,续服用本品。每日监测血压血120/80mmHg左右。
王某某,男,57岁,2年前诊断为原发性高血压。血压的控制一直不理想,最近一次测量血压值为165/105mmHg。病人自述高血压病并未给他带来很多不适,当头痛,心悸等症状出现时,他会服用医生开的降压药。随着症状好转,他常常熬夜加班工作,没有运动锻炼的习惯,嗜烟,偶饮酒。近几日无明显原因头晕伴有精神不振、疲劳乏力、嗜睡多梦、咯吐痰涎等症,经多种理化检查未见明显异常。口服本产品1个月后,主诉精神不振、疲劳乏力及嗜睡多梦病状好转,咯吐痰涎基本消失,血压122/85mmHg。继续服用该产品半个月后头晕、乏力等症消失,时常进行户外活动,已停服西药降压药稳定在120/80mmHg左右。
最后应说明的是:以上各实施例仅用以说明本发明的技术方案,而非对其限制;尽管参照前述各实施例对本发明进行了详细的说明,本领域的普通技术人员应当理解:其依然可以对前述各实施例所记载的技术方案进行修改,或者对其中部分或者全部技术特征进行等同替换;而这些修改或者替换,并不使相应技术方案的本质脱离本发明各实施例技术方案的范围,其均应涵盖在本发明的权利要求和说明书的范围当中。
Claims (8)
1.一种有助于降低血压药食同源组合物组方,其特征在于:包括以下重量份的原料:三七花5-15重量份、玉米须10-20重量份、茯苓10-20重量份、桑叶6-15重量份、荷叶2-8重量份、牛蒡根5-15重量份、山楂5-15重量份、葛根10-20重量份、沙棘2-8重量份、决明子5-15重量份、菊花1-5重量份。
2.根据权利要求1所述的一种有助于降低血压药食同源组合物组方,其特征在于:各原料重量份具体如下:三七花12重量份、玉米须15重量份、茯苓15重量份、桑叶10重量份、荷叶6重量份、牛蒡根12重份、山楂12重量份、葛根15重量份、沙棘6重量份、决明子10重量份、菊花3重量份。
3.一种有助于降低血压药食同源组合物组方的制备工艺,其特征在于:具体包括以下步骤:
步骤1:按重量份称取三七花、玉米须、茯苓、桑叶、荷叶、牛蒡根、山楂、葛根、沙棘、决明子、菊花混合为混合料;
步骤2:将步骤1中的混合料进行粉碎,获得混合料颗粒;
步骤3:将步骤2中所得混合料颗粒进行连续回流提取,获得提取液;
步骤4:将步骤3中所得提取液进行固液分离,获得澄清液;
步骤5:将步骤4所得澄清液进行浓缩,获得浓缩液;
步骤6:将步骤5所得浓缩液进行喷雾干燥,获得干膏粉;
步骤7:将步骤6所得干膏粉中添加辅料获得药食同源组合物,所述辅料包含甜味剂0.1~0.5g/100g。
4.根据权利要求3所述的一种有助于降低血压药食同源组合物组方的制备工艺,其特征在于:所述步骤1中的原料的产地为道地产区。
5.根据权利要求3所述的一种有助于降低血压药食同源组合物组方的制备工艺,其特征在于:所述步骤2中的混合料粉碎粒度为过10目筛。
6.根据权利要求3所述的一种有助于降低血压药食同源组合物组方的制备工艺,其特征在于:所述步骤3中进行两次连续回流提取,第一次加水量为8~15倍原料重量,第二次加水量为6~12倍原料重量,每次提取1~2h。
7.根据权利要求3所述的一种有助于降低血压药食同源组合物组方的制备工艺,其特征在于:所述步骤5中所述浓缩条件为:温度50~70℃,真空-0.08~-0.1Mpa,浓缩液密度为1.05~1.15g/cm3(60℃)。
8.根据权利要求3所述的一种有助于降低血压药食同源组合物组方的制备工艺,其特征在于:所述步骤6中喷雾干燥条件为:进风温度170~200℃,出风温度80~90℃,加料速度350ml/min。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110559269.3A CN113229498A (zh) | 2021-05-21 | 2021-05-21 | 一种有助于降低血压药食同源组合物组方及其制备工艺 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110559269.3A CN113229498A (zh) | 2021-05-21 | 2021-05-21 | 一种有助于降低血压药食同源组合物组方及其制备工艺 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113229498A true CN113229498A (zh) | 2021-08-10 |
Family
ID=77138091
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110559269.3A Pending CN113229498A (zh) | 2021-05-21 | 2021-05-21 | 一种有助于降低血压药食同源组合物组方及其制备工艺 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113229498A (zh) |
-
2021
- 2021-05-21 CN CN202110559269.3A patent/CN113229498A/zh active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101011561B (zh) | 黄连温胆汤现代中药口服制剂及其生产方法 | |
CN104435775A (zh) | 一种中药保健酒及其制备方法 | |
CN112121144B (zh) | 一种刺梨组合物及其制备方法和用途 | |
CN111840363B (zh) | 一种纳豆辅助降血糖保健组合物及其制备方法和用途 | |
CN103961521A (zh) | 一种用于治疗再生障碍性血液病的中药组合物及制备方法 | |
EP3653219A1 (en) | Composition for treating fatty liver | |
CN112336815A (zh) | 一种强体防癌调理三高抗衰老组合物及其应用 | |
CN115317574A (zh) | 一种用于治疗高尿酸血症的组合物及其应用 | |
CN107006856A (zh) | 一种增强耐力、提高抗缺氧耐受力营养剂及其制备方法 | |
CN104857154A (zh) | 一种治疗“三高”症的中药组合物及其制备方法 | |
CN107114781B (zh) | 一种用于保肝的保健食品及其制备方法 | |
CN116370556B (zh) | 一种活血祛瘀、益气安神的中药组合物及其制备方法 | |
CN106581115B (zh) | 含芫根和人参的组合物及其应用 | |
CN108785370A (zh) | 一种用于治疗高血脂症及动脉粥样硬化的药物组合物 | |
CN106109521A (zh) | 一种三七口服液 | |
CN113229498A (zh) | 一种有助于降低血压药食同源组合物组方及其制备工艺 | |
CN108813500B (zh) | 具有补中益气、养血安神和调节人体机能的养生蜂蜜膏 | |
CN112402569A (zh) | 一种抗疲劳保健品及其制备方法 | |
CN110522798A (zh) | 一种主治冠心病的复方制剂及其制备方法 | |
KR101293835B1 (ko) | 황기 및 차전초의 복합 추출물을 유효성분으로 함유하는 비만증의 예방 및 치료용 조성물. | |
CN112089784A (zh) | 中药组合物在制备预防、治疗动脉粥样硬化所致疾病的药物中的应用 | |
CN110959721A (zh) | 一种食凉茶固体饮料 | |
CN112089783B (zh) | 中药组合物在制备预防或/和治疗肥胖的药物中的应用 | |
CN112057535B (zh) | 一种预防或/和治疗血脂异常的中药组合物的制备方法 | |
CN114712458B (zh) | 一种用于治疗高血压病血管衰老的药物组合物及其制备方法、应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication |